The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.

Start Date03 Jul 2024

Sponsor / Collaborator

Apnimed, Inc.

NCT06400615

/ CompletedPhase 2

Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide

Start Date20 May 2024

Sponsor / Collaborator

Apnimed, Inc.

NCT05813275

/ CompletedPhase 3

Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.

Start Date16 Sep 2023

Sponsor / Collaborator

Apnimed, Inc.

100 Clinical Results associated with Aroxybutynin/Atomoxetine

100 Translational Medicine associated with Aroxybutynin/Atomoxetine

100 Patents (Medical) associated with Aroxybutynin/Atomoxetine

Literatures (Medical) associated with Aroxybutynin/Atomoxetine

01 Oct 2025·Contemporary Clinical Trials Communications

Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials

Article

Author: Strollo, Patrick J ; Taranto-Montemurro, Luigi ; Werner, Andrea ; Farkas, Ron ; Cronin, John ; Patel, Sanjay R ; Pho, Huy ; Yee, John

Introduction:

Two key factors leading to obstructive sleep apnea (OSA) pathogenesis include relaxation of upper airway muscles at sleep onset and their insufficient reactivation during obstructive events. Medications that address this neuromuscular dysfunction by increasing upper airway tone during sleep represent a potential strategy for mitigating OSA.

Methods:

AD109 is an investigational, once-daily oral agent taken at bedtime that combines an antimuscarinic, aroxybutynin (2.5 mg), with a selective norepinephrine reuptake inhibitor, atomoxetine (75 mg). LunAIRo (NCT05811247) and SynAIRgy (NCT05813275) are two ongoing, placebo-controlled 51-week and 26-week phase 3 clinical trials, respectively, investigating the efficacy and safety of AD109 to treat mild to severe OSA. Participants include adults with an apnea-hypopnea index with 4% desaturation (AHI₄) >5 who either refuse or fail to tolerate positive airway pressure. Participants (LunAIRo: N = 660; SynAIRgy: N = 646) were randomized 1:1 to receive AD109 or placebo. We hypothesize that AD109 will significantly reduce AHI₄ and symptomatic fatigue compared to placebo in people with OSA. The primary outcome for both trials is the change from baseline to Week 26 in AHI₄ in the AD109 arm versus placebo. Key secondary outcomes include changes from baseline in oxygen desaturation index with 3% desaturation, hypoxic burden based on 4% desaturation, Patient Reported Outcome Measurement Information System (PROMIS)-Fatigue, and proportion of participants with ≥50% reduction in AHI₄ at Week 26.

Discussion:

LunAIRo and SynAIRgy are fully enrolled, large Phase 3 clinical trials designed to confirm and extend our understanding of the safety and efficacy of AD109, a combination oral drug targeting the underlying neuromuscular dysfunction contributing to upper airway muscle collapse during sleep in adults with OSA.

15 Dec 2023·American journal of respiratory and critical care medicine

The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial

Article

Author: Corser, Bruce ; Ojile, Joseph M. ; Taranto-Montemurro, Luigi ; Maynard, James ; Drake, Christopher L. ; Rosenberg, Russell ; Schweitzer, Paula K. ; Thein, Stephen G. ; Abaluck, Brian ; Sangal, R. Bart

Abstract:

Rationale:

Obstructive sleep apnea (OSA) is a common sleep disorder for which the principal treatment option, continuous positive airway pressure, is often poorly tolerated. There is currently no approved pharmacotherapy for OSA. However, recent studies have demonstrated improvement in OSA with combined antimuscarinic and noradrenergic drugs.

Objectives:

The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine, in the treatment of OSA.

Methods:

Phase II randomized, double-blind, placebo-controlled, parallel-group, 4-week trial comparing AD109 2.5/75 mg, AD109 5/75 mg, atomoxetine 75 mg alone, and placebo (www.clinicaltrials.gov identifier NCT 05071612).

Measurements and Main Results:

Of 211 randomized patients, 181 were included in the prespecified efficacy analyses. Sleep was assessed by two baseline and two treatment polysomnograms. Apnea–hypopnea index with a 4% desaturation criterion (primary outcome) was reduced from a median (IQR) of 20.5 (12.3–27.2) to 10.8 (5.6–18.5) in the AD109 2.5/75 mg arm (−47.1%), from 19.4 (13.7–26.4) to 9.5 (6.1–19.3) in the AD109 5/75 mg arm (−42.9%; both P < 0.0001 vs. placebo), and from 19.0 (11.8–28.8) to 11.8 (5.5–21.5) with atomoxetine alone (−38.8%; P < 0.01 vs. placebo). Apnea–hypopnea index with a 4% desaturation criterion decreased from 20.1 (11.9–25.9) to 16.3 (11.1–28.9) in the placebo arm. Subjectively, there was improvement in fatigue with AD109 2.5/75 mg (P < 0.05 vs. placebo and atomoxetine). Atomoxetine taken alone decreased total sleep time (P < 0.05 vs. AD109 and placebo). The most common adverse events were dry mouth, insomnia, and urinary hesitancy.

Conclusions:

AD109 showed clinically meaningful improvement in OSA, suggesting that further development of the compound is warranted.Clinical trial registered with www.clinicaltrials.gov (NCT 05071612).

01 Dec 2022·Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA

Article

Author: Thein, Stephen ; Abaluck, Brian ; Rosenberg, Russell

STUDY OBJECTIVE:

Obstructive sleep apnea is a common and serious sleep disorder for which treatment remains challenging due to lack of adherence to approved therapies. Previous pharmacological studies addressing sleep-related upper airway muscle hypotonia suggested that the combination of atomoxetine and oxybutynin is effective in treating obstructive sleep apnea. The current study is with aroxybutynin (AD109), a new enantiomerically pure form of oxybutynin with better safety profile compared to racemic oxybutynin.

METHODS:

This was a randomized, double-blind, placebo-controlled, crossover study in patients with mild to moderate obstructive sleep apnea. Each received low-dose AD109 (37.5/2.5 mg), high-dose AD109 (75/2.5 mg), and placebo at bedtime across 3 overnight periods in a randomized order. Adverse events were collected by telephone contact with participants during each washout period. The primary endpoint was change in hypoxic burden and secondary endpoint was apnea-hypopnea index.

RESULTS:

Patients treated with both the high and low doses of AD109 had a statistically significant and clinically meaningful difference from placebo in hypoxic burden. Median [interquartile range] hypoxic burden for participants on placebo was 13.9[4.5-21.9] (%min)/h vs 2.3[0.1-10.5] (%min)/h for patients on the high dose (P < .001) and to 7.3[2-12.5] (%min)/h on the low dose (P < .01). Apnea-hypopnea index went from a median of 13.2[8.0-19.1] events/h on placebo reduced to 5.5[2.2 to 9.6] events/h on the high dose (P < .001) and to 7.8[4-13.7] events/h on the low dose (P < .05). AD109 demonstrated a favorable safety profile.

CONCLUSIONS:

This study provides additional support that a pharmacological intervention for obstructive sleep apnea, namely the combination of atomoxetine and aroxybutynin, offers promising results. Additional development of this compound and others is warranted.

CLINICAL TRIAL REGISTRATION:

Registry: ClinicalTrials.gov; Name: AD109 Dose Finding in Mild to Moderate OSA; URL: https://clinicaltrials.gov/ct2/show/NCT04631107; Identifier: NCT04631107.

CITATION:

Rosenberg R, Abaluck B, Thein S. Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA. J Clin Sleep Med. 2022;18(12):2837-2844.

News (Medical) associated with Aroxybutynin/Atomoxetine

11 May 2026

·www.biospace.com

Apnimed Announces Three Oral Presentations and a Late-breaking Poster at the American Thoracic Society (ATS) 2026 International Conference

CAMBRIDGE, Mass. , May 11, 2026 /PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced multiple presentations, including three oral presentations and a late-breaking poster presentation at the upcoming American Thoracic Society (ATS) 2026 International Conference, which will take place May 15-20, 2026, in Orlando, FL. These presentations will feature a pooled analysis of the SynAIRgy and LunAIRo Phase 3 trials of AD109, Apnimed's lead product candidate, reflecting one of the largest clinical development programs conducted for an obstructive sleep apnea pharmacotherapy, alongside insights into reductions in snoring and estimated cardiovascular risk associated with improvements in hypoxic burden with AD109 treatment. ATS 2026 International Conference Presentation Details: Oral Presentations Title: Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea: A Pooled Analysis of the SynAIRgy and LunAIRo Phase 3 Trials Session Type: Scientific Symposium Session Title: A82 Breaking News: Clinical Trial Results in Pulmonary Medicine Session Date, Time: Sunday, May 17, 2026, 2:15-4:15pm EDT Location: Chapin Theater (Level III, OCCC West Concourse) Title: AD109 Significantly Reduces Snoring in Patients with Obstructive Sleep Apnea Session Type: Mini-Symposium Session Title: C21 - From Orexin Agonists to Oxybutynin: A New Era of Pharmacologic Therapies in Sleep Medicine Presentation Date, Time: Tuesday, May 19, 2026, 9:51-10:03am EDT Location: W110A (Level I, OCCC West Concourse) Title: Estimated Reduction in Cardiovascular Risk Associated With Hypoxic Burden Improvement With AD109 in the LunAIRo And SynAIRgy Phase 3 Studies for Obstructive Sleep Apnea Session Type: Mini-Symposium Session Title: C21 - From Orexin Agonists to Oxybutynin: A New Era of Pharmacologic Therapies in Sleep Medicine Session Date, Time: Tuesday, May 19, 2026, 10:15-10:27am EDT Location: W110A (Level I, OCCC West Concourse) Late-breaking Poster Presentation Title: Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea: A Pooled Analysis of the SynAIRgy and LunAIRo Phase 3 Trials Poster Board Number: P194 Session Type: Thematic Poster Session Session Title: A79 – Mechanisms, Endotypes, and Physiologic Control in Sleep Apnea Session Date, Time: Sunday, May 17, 11:30am-1:15pm EDT Location: Area A, Halls WA2-WA3 (Level II, OCCC West Concourse) Poster Presentation Title: Deep Learning Optimization of Sleep Stage Classification Using Wearable-Derived SpO2, Pulse Rate, and Movement Features Poster Board Number: 703 Session Title: A30 - Next-Generation Sleep Diagnostics: AI, Wearables, Sensors, and Transformative Technologies Across the Care Continuum Session Date, Time: Sunday, May 17, 2026, 9:15-11:15am EDT Location: W314 (Level III, OCCC West Concourse) About AD109 AD109 is designed to be the first potential pharmacological treatment to improve oxygenation during sleep and target the neuromuscular root cause of upper airway collapse in people with OSA. It is a first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). AD109 is a once-daily pill taken at bedtime that is designed to lower the complexity of intervention and may help more people benefit from effective, restorative sleep. In a disease characterized by complex and invasive treatment options, AD109, if approved, may offer a convenient oral solution to help improve oxygenation and health for people living with OSA. About Obstructive Sleep Apnea OSA is a serious, chronic sleep-related breathing disease in which the upper airway repeatedly collapses during sleep, leading to intermittent oxygen deprivation. It is caused by two overlapping mechanisms: neuromuscular dysfunction during sleep and predisposing anatomic abnormalities. OSA affects individuals across all walks of life, impacting both males and females of all age groups, ethnicities, and weight classes, including those with or without obesity. An estimated 80 million people in the United States and one billion people worldwide suffer from OSA. An individual with OSA can experience hundreds of sleep apnea events in a single night, each one reducing the blood oxygen levels and negatively impacting cellular functions vital to normal health and function. Failure to effectively treat OSA increases the risk of serious long-term health consequences, including cardiovascular, neurocognitive and cardiometabolic damage and heightened mortality. Yet, many patients diagnosed with OSA remain untreated. About Apnimed Apnimed is a privately held late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. We believe the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. We believe that people with OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of OSA's disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive. Based in Cambridge, Massachusetts, Apnimed is advancing AD109, designed to improve oxygenation in individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Learn more at apnimed.com or follow us on X and LinkedIn . Media Contact: media@apnimed.com Investor Contact: ir@apnimed.com View original content to download multimedia: SOURCE Apnimed, Inc.

Phase 3

07 Apr 2026

·www.pharmaceutical-technology.com

Apnimed obtains up to $150m in funds for commercial launch of AD109

AD109 is designed to improve oxygenation during sleep in people with obstructive sleep apnoea. Credit: daniiD / Shutterstock.com. Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HealthCare Royalty Partners (HCRx) to support the planned launch of AD109. The funding will be used for commercial readiness and the potential US launch of the company’s lead product candidate, AD109, pending approval by the US Food and Drug Administration (FDA). The oral pill launch is intended for the treatment of obstructive sleep apnoea (OSA). Apnimed will initially receive $50m at the deal’s closing. An additional $50m tranche is contingent on FDA approval, with a possible third $50m tranche upon reaching a pre-specified sales milestone, subject to customary closing conditions. The agreement includes a four-year interest-only period, which can be extended to five years on Apnimed achieving a specified net sales milestone. The company will also pay a synthetic royalty at a low single-digit percentage of net sales of AD109 and certain other specified revenues, consistent with standard terms and conditions. Apnimed CEO Larry Miller said: “HCR is a highly respected healthcare investor with deep experience in credit financing, and their investment represents an important validation of our investigational product, AD109 and its commercial potential. “This strategic financing provides significant financial flexibility and supports our continued progress toward the potential US commercialisation of AD109, if approved.” HealthCare Royalty Partners chairman and CEO Clarke Futch said: “With its focused regulatory and commercial strategy for AD109, a novel oral therapy designed to address the root causes of OSA, we believe Apnimed is uniquely positioned to meaningfully impact the treatment landscape for patients living with this serious disease.” AD109 is designed to improve oxygenation during sleep by targeting the neuromuscular root cause of upper airway collapse in people with obstructive sleep apnoea. Apnimed previously announced results from the SynAIRgy and LunAIRo Phase III trials of AD109.

Phase 3License out/in

06 Apr 2026

·www.prnewswire.com

Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch

Strengthens balance sheet to support commercial readiness and planned U.S. launch of AD109 oral pill for the treatment of Obstructive Sleep Apnea (OSA) On track to submit New Drug Application (NDA) for AD109 later this quarter CAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company developing novel oral therapies for obstructive sleep apnea (OSA), today announced that it has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners ("HCRx"). The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed's lead product candidate, AD109, if approved by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, Apnimed will receive $50 million at closing. An additional $50 million tranche will become available upon FDA approval of AD109, and the company may access a third $50 million tranche upon achievement of a pre-specified sales milestone, subject to customary closing conditions. The financing includes an interest-only period of four years, which is extended to five years, if Apnimed achieves a specified net sales milestone. Apnimed also agreed to pay a synthetic royalty equal to a low single-digit percentage of net sales of AD109 and certain other specified revenues, subject to customary terms and conditions. "HCR is a highly respected healthcare investor with deep experience in credit financing, and their investment represents an important validation of our investigational product, AD109 and its commercial potential," said Larry Miller, Chief Executive Officer of Apnimed. "This strategic financing provides significant financial flexibility and supports our continued progress toward the potential U.S. commercialization of AD109, if approved." "With its focused regulatory and commercial strategy for AD109, a novel oral therapy designed to address the root causes of OSA, we believe Apnimed is uniquely positioned to meaningfully impact the treatment landscape for patients living with this serious disease," said Clarke Futch, Chairman and Chief Executive Officer of HealthCare Royalty Partners. "We look forward to supporting Apnimed's continued growth and mission to bring this innovative treatment option to patients as expeditiously as possible." Apnimed previously reported positive results from the pivotal SynAIRgy and LunAIRo Phase 3 trials for AD109, which will support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration, expected later this quarter. About HealthCare Royalty HealthCare Royalty ("HCRx") is a leading royalty acquisition company founded in 2006 that is majority owned by KKR & Co. Inc. (NYSE: KKR). Over two decades, the HCRx team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing $7+ billion in over 110 biopharmaceutical products. With offices in New York, Stamford, San Francisco, Boston, London and Miami, HCRx continues to advance biopharmaceutical innovation by providing innovative capital solutions to counterparties. For more information, visit . HEALTHCARE ROYALTY®, HEALTHCARE ROYALTY PARTNERS® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC. About AD109 AD109 is designed to be the first pharmacological treatment to improve oxygenation during sleep by directly addressing the neuromuscular root cause of upper airway collapse in people with OSA. It is a first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). Their combined pharmacological synergy is designed to target the underlying neuromuscular cause of OSA. AD109 is a once-daily pill taken at bedtime that is designed to lower the complexity of intervention and may help more people benefit from effective, restorative sleep. In a disease characterized by complex and invasive treatment options, AD109 may be a simple solution to help improve oxygenation and health wellbeing for people living with OSA. About Obstructive Sleep Apnea OSA is a serious, chronic sleep-related breathing disease in which the upper airway repeatedly collapses during sleep, leading to intermittent oxygen deprivation. It is caused by two overlapping mechanisms: neuromuscular dysfunction during sleep and predisposing anatomic abnormalities. OSA affects individuals across all walks of life, impacting both males and females of all age groups, ethnicities, and weight classes, including those with or without obesity. An estimated 80 million people in the United States and one billion people worldwide suffer from OSA. An individual with OSA can experience hundreds of sleep apnea events in a single night, each one reducing the blood oxygen levels and negatively impacting cellular functions vital to normal health and function. Failure to effectively treat OSA increases the risk of serious long-term health consequences, including cardiovascular, neurocognitive and cardiometabolic damage and heightened mortality. Yet, many patients diagnosed with OSA remain untreated. About Apnimed Apnimed is a privately held late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. We believe the introduction of simple, once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. We believe that OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive. Based in Cambridge, Mass., Apnimed is advancing AD109, designed to improve oxygenation in individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA and Apnimed plans to submit its New Drug Application (NDA) to the U.S. Food and Drug Administration (the FDA) in the second quarter of 2026. Learn more at apnimed.com or follow us on X and LinkedIn. Media Contact: [email protected] Investor Contact: [email protected] SOURCE Apnimed, Inc. 21% more press release views with Request a Demo

Phase 3NDAClinical ResultAcquisitionLicense out/in

100 Deals associated with Aroxybutynin/Atomoxetine

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Apnea, Obstructive	Phase 3	United States	Apnimed, Inc.	28 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05811247 (LunAIRo, PRNewswire)	Phase 3	Sleep Apnea, Obstructive --	660	Atomoxetine+Aroxybutynin-AD-109	rgmlvtlsjg(nsuxfjmzab) = ortsyaclzr xsfmjcrqtl (ojkfifcxzg ) Met View more	Positive	23 Jul 2025
				placebo	rgmlvtlsjg(nsuxfjmzab) = ukvoxywxsu xsfmjcrqtl (ojkfifcxzg ) Met
NCT05813275 (SynAIRgy, PRNewswire) Manual	Phase 3	Sleep Apnea, Obstructive	-	AD109 (aroxybutynin 2.5mg/atomoxetine 75mg)	gjkxeslpgs(ljlwhjdplp) = hawbwhfchk efpbncdwtf (shlrvzlbjk ) Met View more	Positive	19 May 2025
				Placebo	-
MARIPOSA (ERS2023)	Not Applicable	-	-	AD109 75-2.5mg	qfnlltqnxk(wkjsmbroma) = 44% had an AHI reduction of more than 50%. uwroydopee (qxohqyaqea )	Positive	09 Sep 2023
NCT04580394 (CTgov)	Phase 2	Sleep Apnea, Obstructive	60	Digit System Substitution Test+AD109 (AD109)	hubkrdobvh(prtbfzqpgr) = nbyzvouemq abzwnnbkmc (eoessjgfed, kmbsmpuptz - pmappbdvup)	-	31 Jan 2023
				Digit System Substitution Test+Atomoxetine (Atomoxetine)	hubkrdobvh(prtbfzqpgr) = zlaobkcvpm abzwnnbkmc (eoessjgfed, inqkyvzvvi - qvgjmampcj)
NCT04631107 (CTgov)	Phase 2	Sleep Apnea, Obstructive	32	Placebo+AD109 (AD109 dose1 vs Placebo)	luueplfoux(wwmowdkqew) = qmgsrqoloh qscxsklqae (edhuezmlsb, lxnewhpkcu - wjfpfhabsy) View more	-	22 Dec 2022
				Placebo+AD109 (AD109 dose2 vs Placebo)	luueplfoux(wwmowdkqew) = cwmrcsawtv qscxsklqae (edhuezmlsb, zjjcpipxwp - dqvadyqpur) View more
WSC2022	Phase 2	Sleep Apnea, Obstructive	30	Atomoxetine 75 mg + Aroxybutynin 2.5 mg	swxxvgctyl(znufdgbqev) = avnhjpxmeg fenwdtpyev (dlncfphlqa ) View more	Positive	11 Mar 2022
				Atomoxetine 37.5 mg + Aroxybutynin 2.5 mg	swxxvgctyl(znufdgbqev) = htgavzphnl fenwdtpyev (dlncfphlqa ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Aroxybutynin/Atomoxetine

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation